Far Infrared Treatment for Kidney Diseases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00599391
First received: January 11, 2008
Last updated: January 2, 2009
Last verified: January 2009

January 11, 2008
January 2, 2009
February 2008
October 2008   (final data collection date for primary outcome measure)
Kidney Function Improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00599391 on ClinicalTrials.gov Archive Site
Causes of Mortality [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Far Infrared Treatment for Kidney Diseases
Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.

Renal failure or kidney failure is a situation in which the kidneys fail to function adequately. It is divided into acute and chronic forms; either form may be due to a large number of other medical problems.

There are many causes of chronic kidney disease. The most common cause is diabetes mellitus. Acute renal failure is a rapidly progressive loss of renal function, generally characterized by body fluids disturbances and electrolyte derangement.

It is believed that far infrared radiation of the central nervous system, the endocrine system and the kidneys will help in the management of renal failure and a possible cure.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Kidney Failure
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation for 30 to 40 minutes per session.
1
Far Infrared Radiation
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
10
February 2009
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • People with kidney diseases

Exclusion Criteria:

  • None
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00599391
GAAD-RF-CTP1
Yes
Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Study Chair: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Director: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP